Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 2/20 | 0.62 |
| ▸ | FNTA | P49354 | 16/20 | 0.60 |
| ▸ | FNTB | P49356 | 16/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792125 | 0.89 | GRIA4 (0.78) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL5758052 | 0.88 | GRIA4 (0.64) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL10652865 | 0.87 | GRIA4 (0.60) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL16792138 | 0.86 | FNTA (0.82) | GRIA4FNTAFNTBKMT2A | |
| SCHEMBL16792140 | 0.85 | GRIA4 (0.64) | GRIA4FNTAFNTBKMT2AMAPT | |
| SCHEMBL10651230 | 0.81 | GRIA4 (0.51) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL9865673 | 0.78 | FNTA (0.48) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL3126194 | 0.77 | GRIA4 (0.80) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL10653341 | 0.76 | GRIA4 (0.94) | GRIA4FNTAFNTBKMT2AGRIA2 | |
| SCHEMBL10652875 | 0.75 | GRIA4 (0.74) | GRIA4FNTAFNTBKMT2AGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389206-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7084159-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1389206-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CAO JINGRONG (US) | 2004-02-05 | — | — | US | disclosed |
| US-6642227-B2 | Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-04 | — | — | US | disclosed |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002083667-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-24 | — | — | WO | disclosed |
| US-4994485-A | Seed and soil fungi, bacteria | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1991-02-19 | — | — | US | disclosed |
| EP-0234622-B1 | NEW THIO COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-06-27 | — | — | EP | disclosed |
| EP-0234622-A1 | New thio compounds having fungicidal activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | GRIA4 2812/4885FNTA 2906/4885FNTB 2422/4885 |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | GRIA4 2812/4885FNTA 2906/4885FNTB 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.